Abivax S.A. (ABVX) financials: revenue, earnings and cash flow
Fiscal 2021–2025 · from SEC filings · data as of November 13, 2026
Summary
Abivax’s revenue went from $14M in fiscal 2021 to $5M in fiscal 2025, a decline of about 20.7% a year.
Net income in fiscal 2025 was -$395M, a net margin of -7354.5%; the best year in this period was 2021 with -$48M.
Free cash flow was -$189M in fiscal 2025 and positive in 0 of the 5 years shown.
Revenue, profit and cash flow by year
Income statement
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $5M | $13M | $5M | $5M | $14M |
| Gross profit | — | — | — | — | — |
| Operating income | -$289M | -$180M | -$141M | -$69M | -$47M |
| Net income | -$395M | -$183M | -$163M | -$65M | -$48M |
| EPS (diluted) | $-4.53 | $-2.10 | $-1.87 | $-0.74 | $-0.55 |
| R&D | — | — | — | — | — |
| Revenue growth | −58.5% | +153.3% | +4.5% | −63.9% | — |
Cash flow
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$189M | -$160M | -$107M | -$58M | -$51M |
| Capital spending | -$166851 | -$664894 | -$292824 | -$307180 | -$53232 |
| Free cash flow | -$189M | -$161M | -$108M | -$58M | -$51M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Buybacks | — | — | — | — | — |
| Stock-based pay | $42M | $21M | $9M | -$1M | $937797 |
Balance sheet
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash | $607M | $150M | $278M | $29M | $69M |
| Debt | $0 | $0 | $0 | $0 | $0 |
| Equity | $535M | $42M | $217M | $8M | $29M |
| Total assets | $687M | $213M | $361M | $81M | $124M |
| Shares (diluted) | 87M | 87M | 87M | 87M | 87M |
Margins and returns
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Gross margin | — | — | — | — | — |
| Operating margin | -5384.2% | -1389.5% | -2756.5% | -1414.7% | -346.1% |
| Net margin | -7354.5% | -1415.7% | -3197.1% | -1325.3% | -354.9% |
| FCF margin | -3528.9% | -1242.8% | -2107.7% | -1183.2% | -377.0% |
| ROIC | -42.7% | -426.2% | -65.0% | -901.9% | -159.6% |
| ROE | -73.8% | -434.3% | -75.4% | -844.9% | -163.7% |
Frequently asked questions
What is Abivax’s annual revenue?
$5M in fiscal 2025.
How much profit does Abivax make?
Net income was -$395M in fiscal 2025 (net margin -7354.5%).
Is Abivax’s revenue growing?
No: revenue fell 58.5% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.